FLT3 and acute myeloid leukemia: Treatment of primary human FLT3 mutant AML blast mononuclear cells (FLT3-ITD) with 50 nM OTS167 also resulted in loss of FLT3 protein expression at 24 h (Fig. 1B, C and Table 1).